{"id":"W2804378061","doi":"10.1158/1078-0432.ccr-18-0613","title":"Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech","keywords":"Fulvestrant; Breast cancer; Cancer; Medicine; Internal medicine; Oncology; Hormone receptor; Phases of clinical research; Hormone; Metastatic breast cancer; Toxicity; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009370115,0.001205731,0.001542066,0.0003311204,0.0002504218,0.0005556568,0.0006067551,0.0006326272,0.002678022],"category_scores_gemma":[0.0005271102,0.000502884,0.0008283613,0.0003202045,0.0005719627,0.0004710356,0.0002484153,0.002081781,0.0007645145],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006198179,"about_ca_system_score_gemma":0.001224156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007518374,"about_ca_topic_score_gemma":0.001916671,"domain_scores_codex":[0.9998012,0.00009149081,0.00001112082,0.00003558168,0.00002119945,0.00003944758],"domain_scores_gemma":[0.9996318,0.00004659309,0.00007387937,0.00002727602,0.00002109201,0.0001993792],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6466423,0.08181971,0.00981632,0.001056595,0.00206302,0.0003847819,0.0003223949,0.004001917,0.1137288,0.0002690517,0.003727248,0.1361678],"study_design_scores_gemma":[0.5936208,0.3871318,0.009905925,0.00002595883,0.0003987242,0.0003041108,0.00003613146,0.001586362,0.005189172,0.0000946041,0.001685219,0.00002114671],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960283,0.001209672,0.000410063,0.0002081023,0.00006205186,0.0009720027,0.0003175185,0.00006832491,0.0007239085],"genre_scores_gemma":[0.9945468,0.0009741827,0.001077105,0.0003270782,0.00008970065,0.001011566,0.0008190605,0.00001764819,0.001136912],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002678022,"threshold_uncertainty_score":0.008958817,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06313931023451126,"score_gpt":0.4699763740301713,"score_spread":0.40683706379566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}